The Current Ratio as of December 2025 (TTM) for Advagene Biopharma Co., Ltd. (6709.TWO) is 30.83

According to Advagene Biopharma Co., Ltd.’s latest financial reports and current stock price. The company's current Current Ratio is 30.83. This represents a change of 36.51% compared to the average of 22.59 of the last 4 quarters.

Advagene Biopharma Co., Ltd. (6709.TWO) Historical Current Ratio (quarterly & annually)

How has 6709.TWO Current Ratio performed in the past?

The mean historical Current Ratio of Advagene Biopharma Co., Ltd. over the last ten years is 25.11. The current 30.83 Current Ratio has changed 12.18% with respect to the historical average. Over the past ten years (40 quarters), 6709.TWO's Current Ratio was at its highest in in the December 2019 quarter at 32.77. The Current Ratio was at its lowest in in the June 2019 quarter at 0.

Advagene Biopharma Co., Ltd. (6709.TWO) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Advagene Biopharma Co., Ltd. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Advagene Biopharma Co., Ltd. (6709.TWO) Average Current Ratio

How has 6709.TWO Current Ratio performed in the past?

The current Current Ratio of Advagene Biopharma Co., Ltd. (6709.TWO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Advagene Biopharma Co., Ltd. (6709.TWO) Current Ratio vs. Peers

How is 6709.TWO’s Current Ratio compared to its peers?

Advagene Biopharma Co., Ltd.’s Current Ratio is greater than Chunghwa Chemical Synthesis & Biotech Co., Ltd. (3.34), greater than Genomics BioSci & Tech. Co.,Ltd. (1.35), greater than Sunny Pharmtech Inc. (1.30), greater than Greenyn Biotechnology Co., Ltd (6.47), greater than Meribank Biotech Co., Ltd (1.58), greater than Hcmed (6.86), greater than InnoPharmax Inc. (6.80), greater than Shangya Technology Co., Ltd. (3.33), greater than Enimmune corporation (1.41), greater than NaviFUS Corp. (15.39),

Build a custom stock screener for Advagene Biopharma Co., Ltd. (6709.TWO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Advagene Biopharma Co., Ltd. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Advagene Biopharma Co., Ltd. (6709.TWO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Advagene Biopharma Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.